The FDA is continuing to evaluate the risks and benefits of devices approved for managing and treating patients who have opioid use disorder.
In 2019, a team of stakeholders from Stanford University and the FDA began performing risk−benefit analyses of devices approved for these patients as part of the FDA’s Centers of Excellence in Regulatory Science and Innovation.
The committee is now updating its mission to get a better feel for patient preferences, and provided a description of